The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Luspatercept benefits MF-associated anemia
Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the initial results of the ongoing open-label, phase 2 trial evaluating luspatercept in patients with myelofibrosis (MF)-anemia (NCT03194542). The interim results suggest clinically significant activity of luspatercept in this group, including those receiving concomitant ruxolitinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
